Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| UCHI | SCBRMGHC | |
|---|---|---|
| Only in UCHI | ||
| WuXi Biologics | 9.94% | N/A |
 BeOne | 9.29% | N/A |
| Innovent | 8.62% | N/A |
 Wuxi AppTec | 8.42% | N/A |
| Only in SCBRMGHC | ||
 Eli Lilly and Co | N/A | 9.70% |
 Johnson & Johnson | N/A | 7.85% |
 ABBVIE | N/A | 4.98% |
 Unitedhealth Group | N/A | 4.31% |
30 Dec 2025 → 30 Oct 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| SCBRMGHC | +10.74% | 16.87% | 0.64 |
| UCHI | −2.77% | 29.74% | −0.09 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | UCHI | SCBRMGHC |
|---|---|---|
Fund details | ||
| Fund size | 699 million | 2,422 million |
| Inception date | 25 Feb 2021 | 6 Nov 2015 |
| Master fund | กองทุนที่ลงทุนหลายกอง (Global X China Biotech, Kraneshares MSCI All China Health Care Index) | Janus Henderson Global Life Sciences Fund |
| Dividend policy | Does not pay | Does not pay |
Risk and currency hedging | ||
| Risk level | 7 | 7 |
| Hedging policy | Hedged at the manager's discretion | Almost fully hedged |
| Share hedged | 89.92% | 100.58% |
Minimum purchase and redemption | ||
| First purchase | 0.01 THB | 1,000 THB |
| Subsequent purchase | 0.01 THB | 1,000 THB |
| Redemption (amount) | 0.01 THB | 1,000 THB |
| Redemption (units) | No minimum | No minimum |
| Balance (amount) | No minimum | 1,000 THB |
| Balance (units) | No minimum | No minimum |
Order cut-off and redemption payment | ||
| Buy before | 15:30 | 15:30 |
| Redeem before | 14:00 | 15:30 |
| Redemption paid | T+4 | T+5 |
